Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days episode artwork

EPISODE · Mar 20, 2026 · 10 MIN

Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, retatrutide, Eli Lilly, TRANSCEND-T2D-1, Wegovy HD, Novo Nordisk, semaglutide, CNPV, CollegiumPharmaceutical, Corium, Azstarys, ADHD, Pfizer, Talzenna, talazoparib,TALAPRO-3, prostate cancer, Lynavoy, linerixibat, Alfasigma, GSK, primary biliary cholangitis, CSL, Hemgenix, gene therapy, ACIP, AstraZeneca, Shanghai, obesity, Type 2 diabetes, GLP-1, triple agonist, PARP inhibitor, Lilly, Merck, Sanofi, Moderna

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, retatrutide, Eli Lilly, TRANSCEND-T2D-1, Wegovy HD, Novo Nordisk, semaglutide, CNPV, CollegiumPharmaceutical, Corium, Azstarys, ADHD, Pfizer, Talzenna, talazoparib,TALAPRO-3, prostate cancer, Lynavoy, linerixibat, Alfasigma, GSK, primary biliary cholangitis, CSL, Hemgenix, gene therapy, ACIP, AstraZeneca, Shanghai, obesity, Type 2 diabetes, GLP-1, triple agonist, PARP inhibitor, Lilly, Merck, Sanofi, Moderna

NOW PLAYING

Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days

0:00 10:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 10 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on March 20, 2026.

What is this episode about?

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M,...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!